Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5276978 | 0.89 | TSHR (0.40) | TSHRPTK2BALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL5237304 | 0.88 | TSHR (0.43) | TSHRPTK2BALDH1A1KMT2ANPSR1 | |
| SCHEMBL5237718 | 0.88 | TSHR (0.42) | TSHRPTK2BALDH1A1MEN1KMT2A | |
| SCHEMBL5234899 | 0.87 | NPSR1 (0.45) | TSHRPTK2BMEN1KMT2ARAB9A | |
| SCHEMBL5266554 | 0.87 | TSHR (0.40) | TSHRPTK2BKMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL5239302 | 0.86 | TSHR (0.39) | TSHRPTK2BALDH1A1MEN1KMT2A | |
| SCHEMBL5232665 | 0.85 | TSHR (0.38) | TSHRPTK2BSMN1; SMN2NPSR1CASP3 | |
| SCHEMBL5232612 | 0.84 | NPSR1 (0.44) | TSHRPTK2BMEN1KMT2ARAB9A | |
| SCHEMBL5239586 | 0.83 | SMN1; SMN2 (0.48) | TSHRPTK2BMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5233201 | 0.83 | ALDH1A1 (0.46) | TSHRPTK2BALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355886-B1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-7034039-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-25 | — | — | US | disclosed |
| US-20040082607-A1 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082607-A1 | Fused heterocyclic compounds | DPP7, DPP4, METAP1 | TSHR 2475/4885PTK2B 3599/4885ALDH1A1 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.